Age‐associated endocrine deficiencies as potential determinants of femoral neck (type II) osteoporotic fracture occurrence in elderly men

Boonen, Steven; Vanderschueren, Dirk; Geusens, Piet; Bouillon, Roger

doi:10.1046/j.1365-2605.1997.00047.x

Cited by 28 publications

(12 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Low IGF-I values have been reported in hip fracture subjects (31,32) and also in our study baseline IGF-I values were low. These findings suggest that resistance to GH action, described for catabolic and surgical trauma patients (33), may also be a feature of patients with hip fracture.…”

Section: Discussionsupporting

confidence: 71%

Use of human GH in elderly patients with accidental hip fracture

Lely

Lamberts²,

Jauch³

et al. 2000

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: To investigate whether early intervention with recombinant human growth hormone (hGH) after hip fracture improves functional recovery and long-term outcome. Subjects and methods: Functional recovery after hip fracture is often incomplete. The catabolic situation that develops after the hip fracture accident, and a state of malnutrition either pre-existing or developing after surgery, are main contributing factors for the poor clinical outcome. hGH has been used to promote anabolism in a variety of clinical catabolic situations. The study design was randomized, double-blind and placebo-controlled. A total of 111 patients older than 60 years with an accidental hip fracture (mean age 78X5^9X1 (S.D.) years) were randomized to receive either hGH (20 mg/kg per day) or placebo for a period of 6 weeks, starting within 24 h after the hip fracture accident. Thereafter patients were followed up for an additional period of 18 weeks. Efficacy was assessed by comparing the changes in the Barthel Index score of activities of daily living and in a patient's living situation between the hGH-and the placebo-treated subjects. Results: Eighty-five (78.5%) patients completed the first 8 weeks of the study and 76 (68.5%) the entire study period of 24 weeks. When split according to age, a trend was found that for patients older than 75 years the changes in Barthel Index score from baseline were less in the hGH group than in the placebo group 218X6^18 vs 228X1^26 at 6 weeks after surgery P , 0X075X There was an overall trend to a higher rate of return to the pre-fracture independent living situation in the hGH group than in the placebo group. Analysis by age revealed a significantly higher proportion of hGHthan placebo-treated patients returning to the pre-fracture living situation for subjects older than 75 years (93.8 vs 75.0%, P 0X034X hGH treatment increased IGF-I values to levels in the range of those of normal subjects of 50±60 years of age. Conclusions: A 6 week treatment with hGH (20 mg/kg per day) of otherwise healthy patients after an accidental hip fracture may be of benefit if given to subjects older than 75 years of age. The rate of return to the pre-fracture living situation in subjects of this age treated with hGH was significantly increased when compared with the placebo-treated group. The treatment intervention was well tolerated and no safety issues were recorded.

show abstract

Section: Discussionsupporting

confidence: 71%

Use of human GH in elderly patients with accidental hip fracture

Lely

Lamberts²,

Jauch³

et al. 2000

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…This stimulates the secretion of PTH and induces age-associated secondary hyperparathyroidism, which enhances bone turnover and accelerates bone loss [2]. Adequate intake of calcium and vitamin D, through diet and/or supplements, reverses this secondary hyperparathyroidism and is recommended in the prevention of osteoporotic fractures [1, 3].…”

Section: Calciummentioning

confidence: 99%

Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications

et al. 2012

Self Cite

View full text Add to dashboard Cite

SummaryDrugs used for the prevention and the treatment of osteoporosis exert various favourable and unfavourable extra-skeletal effects whose importance is increasingly recognized notably for treatment selection.IntroductionThe therapeutic armamentarium for the prevention and the treatment of osteoporosis is increasingly large, and possible extra-skeletal effects of available drugs could influence the choice of a particular compound.MethodsThe present document is the result of a national consensus, based on a systematic and critical review of the literature.ResultsObservational research has suggested an inverse relationship between calcium intake and cardiovascular diseases, notably through an effect on blood pressure, but recent data suggest a possible deleterious effect of calcium supplements on cardiovascular risk. Many diverse studies have implicated vitamin D in the pathogenesis of clinically important non-skeletal functions or diseases, especially muscle function, cardiovascular disease, autoimmune diseases and common cancers. The possible effects of oral or intravenous bisphosphonates are well-known. They have been associated with an increased risk of oesophageal cancer or atrial fibrillation, but large-scale studies have not found any association with bisphosphonate use. Selective oestrogen receptor modulators have demonstrated favourable or unfavourable extra-skeletal effects that vary between compounds. Strontium ranelate has a limited number of non-skeletal effects. A reported increase in the risk of venous thromboembolism is not found in observational studies, and very rare cases of cutaneous hypersensitivity reactions have been reported. Denosumab has been introduced recently, and its extra-skeletal effects still have to be assessed.ConclusionSeveral non-skeletal effects of bone drugs are well demonstrated and influence treatment choices.

show abstract

“…In spite of the beneficial effect of testosterone on bone mass, ordinary osteoporosis therapeutics are usually selected (Boonen et al 1997). …”

Section: Discussionmentioning

confidence: 99%

Bisphosphonate related osteonecrosis of the jaws (BRONJ) in osteoporotic males

et al. 2016

View full text Add to dashboard Cite

BackgroundThe purpose of this study was to describe the clinical characteristics of bisphosphonate related osteonecrosis of the jaws (BRONJ) in osteoporotic males.MethodsThe medical records of BRONJ patients from 2007 to 2014 were reviewed. The data from only the male patients was extracted, and demographic data was collected and biochemical markers were measured.Results11 Patients out of 210 (5 %) being males. Among the 11 patients, the indication of bisphosphonate (BP) was osteoporosis in 9 patients, and cancer in two. In one of the osteoporosis patients, osteoporosis was thought to be secondary to hypogonadism after testicular tumor resection. Serum c-terminal telopetide crosslink of type I collagen (s-CTX) values ranged from 60 to 165 pg/mL (mean: 84.6 ± 36.8, median: 70). Serum osteocalcin (s-OC) ranged from 0 to 5.06 ng/mL (mean: 1.83 ± 1.66, median: 1.5) and vitamin D ranged from 0 to 11.9 (mean: 5.02 ± 4.92, median: 3.5).ConclusionBRONJ can be overlooked in male patients with osteoporosis. Although the incidence of BRONJ in males may be low, dentists should also check if their male patients are on osteoporosis treatment since osteoporosis in males can be manifested as a secondary disease to hypogonadism.

show abstract

Age‐associated endocrine deficiencies as potential determinants of femoral neck (type II) osteoporotic fracture occurrence in elderly men

Cited by 28 publications

References 72 publications

Use of human GH in elderly patients with accidental hip fracture

Use of human GH in elderly patients with accidental hip fracture

Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications

Bisphosphonate related osteonecrosis of the jaws (BRONJ) in osteoporotic males

Contact Info

Product

Resources

About